Download PDF
Dtsch Med Wochenschr 2013; 138(41): 2107-2110
DOI: 10.1055/s-0033-1349604
Kommentar | Commentary
Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Adjuvante Chemotherapie bei Weichteilsarkomen? Ein klares „Jein“

Adjuvant chemotherapy for soft tissue sarcoma? A clear no – well – yes-ish
A. Abendroth
1   Innere Klinik (Tumorforschung), Sarkomzentrum, Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Universität Duisburg – Essen
,
S. Bauer
1   Innere Klinik (Tumorforschung), Sarkomzentrum, Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Universität Duisburg – Essen
› Author Affiliations
Further Information

Publication History

18 July 2013

22 August 2013

Publication Date:
01 October 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Weichteilsarkom - adjuvante Chemotherapie - Risikofaktoren

Keywords

soft tissue sarcoma - adjuvant chemotherapy - risk factors
 

  • Literatur

  • 1 Antonescu CR. The role of genetic testing in soft tissue sarcomas. Histopathology 2006; 48: 13-21
    CrossrefPubMedGoogle Scholar
  • 2 Elias AD. Future directions in the management of soft sarcomas. Hematol Oncol 1992; 10: 53-60
    CrossrefPubMedGoogle Scholar
  • 3 ESMO/European Sarcoma Networking Group. soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: 92-99
    CrossrefPubMedGoogle Scholar
  • 4 Fletcher CDM, Gridge JA, Hogendoorn PCW, Mertens F. WHO classification of tumours of soft tissue and bone, . 4th ed. International Agency for Research on Cancer; 2013
    Google Scholar
  • 5 Frustraci S, De Paoli A, Bidoli E et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003; 65: 80-84
    CrossrefPubMedGoogle Scholar
  • 6 Frustraci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian Randomized Cooperative Trial. J Clin Oncol 2001; 19: 1238-1247
    CrossrefPubMedGoogle Scholar
  • 7 Gerrand CH, Billingham LJ, Woll PJ et al. Follow up after primary treatment of soft tissue sarcoma: a survey of current practice in the United Kingdom. Sarcoma 2007; Article ID 34128
    PubMedGoogle Scholar
  • 8 Gronchi A, Frustraci S, Mercuri M et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas. J Clin Oncol 2012; 30: 850-856
    CrossrefPubMedGoogle Scholar
  • 9 Hensley ML, Ishill N, Soslow R et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol 2009; 112: 563-7
    CrossrefPubMedGoogle Scholar
  • 10 Italiano A, Delva F, Mathoulin-Pelissier S et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas. Ann Oncol 2010; 21: 2436-2441
    CrossrefPubMedGoogle Scholar
  • 11 Jones B, Komarnitsky P, Miller GT et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs 2012; 2: 173-84
    PubMedGoogle Scholar
  • 12 Klingenbiehl T, Boos J, Beske F et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS-96 trial. Pediatr Blood Cancer 2008; 50: 739-745
    CrossrefPubMedGoogle Scholar
  • 13 NCCN. National Comprehensive Cancer Network Guidelines Soft Tissue Sarcoma. . Version 3. 2012
    PubMedGoogle Scholar
  • 14 Ölschläger K, Hoiczyk M, Ahrens M, Podleska L, Täger G, Treckmann J, Pöttgen C, Schuler M, Bauer S. Chemotherapy in resectable sarcomas with complex karyotype – a single center retrospective analysis. Stuttgart: DGHO Jahrestagung; 2012 a506
    PubMedGoogle Scholar
  • 15 Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113: 573-81
    CrossrefPubMedGoogle Scholar
  • 16 Pisters P, O´Sullivan B, Maki R. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol 2007; 25: 1003-1008
    CrossrefPubMedGoogle Scholar
  • 17 Pisters PW, Leung DH, Woodruff J et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14 (05) 1679-89
    CrossrefPubMedGoogle Scholar
  • 18 Ravi V, Patel S. Adjuvant chemotherapy for soft tissue sarcoma. Surg Oncol Clin N Am 2012; 21: 243-253
    CrossrefPubMedGoogle Scholar
  • 19 Schütte J, Hartmann JT, Reichardt P, Issels RD, Tunn P-U, Budach V. Weichteilsarkome. http://www.dgho-onkopedia.de/de/onkopedia/leitlinien/weichteilsarkome (letzter Zugriff 17.9.2013)
    Google Scholar
  • 20 Somaiha N, von Mehren M. New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Management Res 2012; 4: 397-411
    PubMedGoogle Scholar
  • 21 Spiro IJ, Gebhardt MC, Jennings C et al. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 1997; 24: 540-46
    PubMedGoogle Scholar
  • 22 Tierney JF. Sarcoma Meta-Analysis Collaboration: Adjuvant chemotherapy for localized respectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350: 1647-54
    CrossrefPubMedGoogle Scholar
  • 23 van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886
    CrossrefPubMedGoogle Scholar
  • 24 Weiss SW, Goldblum JR. Soft Tissue Tumors. Mosby Elsevier; 2008
    Google Scholar
  • 25 Woll PJ, Reichardt P, Le Cesne A et al. Adjuvant chemotherapy with doxorubicin, ifosfamide and lenograstim for resected soft-tissue sarcome (EORTC 62931). Lancet Oncol 2012; 1045-1054
    PubMedGoogle Scholar